The notice of meeting which contains the agenda, the full text of the draft resolutions as well as the main terms of participation and voting at the General Meeting can be found on the Investor section of the Company's website.
Considering the context of health crisis linked to the COVID-19 pandemic, the terms of participation and voting at this General Meeting may change depending on the evolution of the health and/or regulatory situation. Shareholders are invited to regularly consult the section dedicated to the General Meeting on the Company's website: www.maatpharma.com/investor-2/#GM.
Prior to the consideration of the items of the agenda, this General Meeting will be an opportunity to review and discuss the Company's latest developments over the past months.
This notice and all preparatory documents for the General Meeting will be available for consultation in accordance with applicable legal and regulatory provisions at the Company's registered office and on the Investor section of the Company's website.
As a reminder, the annual shareholders' General Meeting of the Company which will, inter alia, deliberate on the financial statements for the year ended
About
The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations.
Contact:
Tel: 04 28 29 14 00
(C) 2022 Electronic News Publishing, source